Detalles de la búsqueda
1.
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.
J Autoimmun
; 125: 102744, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34781162
2.
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.
J Transl Autoimmun
; 7: 100212, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37854035
3.
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies.
Curr Pharm Des
; 28(24): 2022-2028, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35726427
4.
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments.
Curr Pharm Des
; 27(41): 4245-4252, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34477509
5.
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.
Clin Rheumatol
; 39(11): 3195-3204, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32852623
6.
Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).
PLoS One
; 13(10): e0205134, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30356301
7.
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study.
Lancet Rheumatol
; 3(3): e166-e168, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33521657
Resultados
1 -
7
de 7
1
Próxima >
>>